Loading...
•
Sep 30, 2021
Atai Q3 2021 Earnings Report
atai reported financial results and provided a corporate update for Q3 2021.
Key Takeaways
atai Life Sciences reported its Q3 2021 financial results, highlighting positive momentum after its IPO in June with 11 therapeutic programs underway. The company saw positive Phase 2b data from COMPASS Pathways and initiated two new clinical trials. Atai also launched atai Impact, a philanthropic program to support innovative mental health approaches.
Positive topline results from COMP360’s Phase 2b study
RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4
Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort
Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change